A2M: A Drug Target / Disease Biomarker (G2)

Target Name: A2M

NCBI ID: G2

Content of Review Report on A2M Target / Biomarker

A2M

A2M: A Drug Target / Disease Biomarker

A2M, short for A2M001, is a drug target and a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Developed by the biotechnology company, A2M Biosciences, A2M001 is a small molecule that targets the protein p18, which is expressed in high levels in cancer cells.

The discovery of A2M001 comes from a team of researchers led by Dr. Paul W. Murray, a renowned professor of pharmacology at the University of Cambridge, UK. Dr. Murray's team identified p18 as a potential drug target due to its over-expression in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The team then developed A2M001, a small molecule that binds to p18 and inhibits its activity.

A2M001's unique structure and ability to specifically target p18 make it an attractive drug candidate. The small molecule can be easily synthesized and tested for its efficacy in various diseases. Additionally, its structure allows for the development of different chemical modifications, which can further improve its binding affinity and potency.

In preclinical studies, A2M001 has shown promise in treating various diseases. For example, A2M001 has been shown to effectively inhibit the growth of cancer cells in cell culture and in animal models. It has also been shown to reduce the neurodegeneration caused by various diseases, such as Alzheimer's and Parkinson's.

A2M001's potential in treating psychiatric disorders is particularly exciting. The team has identified that A2M001 can effectively treat depression and anxiety in animal models. Additionally, clinical trials are underway to evaluate its safety and efficacy in treating human depression and anxiety.

The team behind A2M001 is confident that it has the potential to become a valuable tool for the treatment of various psychiatric disorders. We are excited about the potential of A2M001 to revolutionize the treatment of psychiatric disorders, said Dr. Murray. Our data indicate that A2M001 has the potential to become a first-in-class treatment for depression and anxiety.

While the development of A2M001 is a promising step forward in the treatment of psychiatric disorders, it is important to note that further research is needed to fully understand its safety and effectiveness. We are currently in the early stages of testing A2M001, and we look forward to continuing these studies and evaluating its potential, said Dr. Murray.

In conclusion, A2M001 is a drug target and a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its unique structure and ability to specifically target p18 make it an attractive drug candidate. While further research is needed to fully understand its safety and effectiveness, the potential of A2M001 is exciting for the treatment of various psychiatric disorders.

Protein Name: Alpha-2-macroglobulin

Functions: Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region, a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase

The "A2M Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about A2M comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets